Use of Vertigoheel® in patients with dizziness due to chronic cerebral ischemia (research results)

Introduction. One of the most common symptoms of chronic cerebral ischemia (CCI) is dizziness, which significantly reduces the quality of life of patients. Aim. Тo evaluate the effects of Vertigoheel® in treatment of patients with dizziness due to CCI in comparison with betahistine and a nootropic drug (choline alfoscerate) after 3 weeks in real clinical practice. Materials and methods . A prospective comparative observational study was conducted among 30 patients diagnosed with CCI, whose main complaint was dizziness. Patients were divided into 3 groups, 10 patients in each group: the first group received Vertigoheel® in addition to the standard treatment of CCI with choline alfoscerate; the second group took choline alfoscerate and betahistine; the third group – only choline alfoscerate. At the first visit and in dynamics (after 1 and 3 weeks), a neurological examination was performed, testing using the DHI, HADS and VAS scales. Results. Against the background of combined treatment, a decrease in the degree of dizziness was noted to the absence in the first group (11.4 ± 8.5 points) and mild in the second (22.8 ± 10.3 points) according to the average score on the DHI scale, with an initially lower overall average score in the first group. Positive dynamics were also observed for all DHI subscales in the combined treatment groups on days 7 ± 2 and 21 ± 2. During monotherapy in the third group, no clinically significant decrease in dizziness was found with an insignificant decrease in the average score on the DHI scale and its subscales. A decrease in anxiety and depression was recorded in all groups. Conclusions. The bioregulatory therapy product has a therapeutic effect comparable to betahistine when used in combination with a nootropic drug in patients with dizziness associated with CCI.